References
- Armstrong AW. Psoriasis. JAMA Dermatol. 2017;153(9):956.
- Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342–350.
- Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 Cytokines. Curr Rheumatol Rep. 2007;9(6):461–467.
- Nestle FO, Meglio PD, Qin J-Z, et al. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9:679–691.
- Winterfield LS, Menter A, Gordon K, et al. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis. 2005;64:ii87–ii90.
- Oliveira M, Rocha B, Duarte G. Psoriasis: classical and emerging comorbidities. Annais Brasileiros de Dermatologia. 2015;90(1):9–20.
- Lebwohl M. Does treatment of psoriasis reduce cardiovascular comorbidities? J Investigative Dermatol. 2017;137(8):1612–1613.
- Lebwohl M, Ting PT, Koo JYM. Psoriasis treatment: traditional therapy. Ann Rheum Dis. 2005;64:ii83–ii86.
- Deeks ED. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2015;75(12):1393–1403.
- Aslam A, Griffiths CEM. Drug therapies in dermatology. Clinical medicine. J R Coll Physicians Lond. 2014;14(1):47–53.
- Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venereol. 2014;95(2):133–139.
- Johnson-Huang LM, Lowes MA, Krueger JG. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech. 2012;5:423–433.
- Feely MA, Smith BL, Weinberg JM. Novel psoriasis therapies and patient outcomes, part 3: systemic medications. Cutis. 2015;96:47–53.
- Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–1276.
- A study to assess efficacy and safety of filgotinib in active psoriatic arthritis (EQUATOR). ClinicalTrials.gov. Galapagos, NV: ClinicalTrials.gov/NIH, 2010. Available at: https://clinicaltrials.gov/ct2/show/NCT03101670 [Last accessed 2018 Apr 4].
- Abi-Saab W, Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–874.
- Andersen PM. Pivotal efficacy and safety registration trial of FP187 in moderate to severe plaque psoriasis. ClinicalTrials.gov. Dresden, Germany: ClinicalTrials.gov/NIH, 2010. Available at: https://clinicaltrials.gov/ct2/show/study/NCT01230138?term=FP187&rank=1 [Last accessed 2018 Apr 4
- Kim R. XenoPort announces positive phase 2 study results for XP23829 as a potential treatment for patients with psoriasis. Xenoport. Santa Clara, CA: Xenoport, 2015. Available at: http://files.shareholder.com/downloads/XNPT/0x0x850454/1C6B2BD2-A70F-42FA-895F-02F8B5DB948A/XNPT_News_2015_9_15_Clinical.pdf [Last accessed 2018 Apr 4
- Zanin-Zhorov A, Weiss JM, Trzeciak A, et al. Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10. J Immunol. 2017;15;198(10):3809–3814.
- Prurisol: A New Small Molecule under investigation for the treatment of Psoriasis. Cellceutix. Beverly, MA: Cellceutix Corporation; 2016. [Last accessed 2018 Apr 4. Available at https://static1.squarespace.com/static/5715352e20c647639137f992/t/583f7f14bebafbe20767391b/1480556310644/Prurisol-Presentation-for-Med-Derm-RD-Workshop_19Sep2016-u.pdf
- Drug in development may one day pack the power of a biologic into a pill, according to early trial results. National Psoriasis Foundation. Alexandria, VA: National Psoriasis Foundation; 2016. Available at https://www.psoriasis.org/advance/drug-development-may-one-day-pack-power-biologic-pill-according-early-trial-results
- Gege C. RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345 (2016). Expert Opin Ther Pat. 2016;27(1):1–8.
- Zampeli E, Tiligada E. The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol. 2009;157(1):24–33.
- Milutinovic M. A study to determine the efficacy of ZPL-3893787 in subjects with plaque psoriasis. ClinicalTrials.gov. Mobile, AL: ClinicalTrials.gov/NIH, 2018. Available at: https://clinicaltrials.gov/ct2/show/NCT02618616?term=zpl+389 [Last accessed 2018 Apr 4
- Khan D, Ahmed SA. Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs. Front Genet. 2015;6:1–236.
- Pescarono G. Available from:http://flipper.diff.org/app/pathways/1226 [Last accessed 4 April 2018]
- Om A, Hill D, Feldman SR. Therapy for Severe Psoriasis. Philadelphia: Elsevier; 2017.
- Rigopoulos D, Ioannides D, Chaidemenos G, et al. Patient preference study for different characteristics of systemic psoriasis treatments (Protimisis). Dermatol Ther. 2018;31(3): e12592.
- Eliasson L, Bewley AP, Mughal F, et al. Evaluation of psoriasis patients’ attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments. Patient Prefer Adherence. 2017 Feb 28;11:353–362. eCollection. eCollection.
- Stewart KD, Johnston JA, Matza LS, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016;10:1385–1399.
- Efficacy of Baricitinib vs. Enbrel and Humira, Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther Clin Risk Manag. 2008;4(2):345–351.
- Gieselbach RJ, Muller-Hansma AH, Wijburg MT, et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol. 2017 Jun;264(6):1155–1164.
- Advantages and Disadvantages of PASI 75 vs. PASI 90/100. A Tale of Two Psoriasis Numbers: PASI 75 or 90? Debate over complete clearance goals ends in draw. MedPage Today. New York, NY: AAD, 2016. Available at: https://www.medpagetoday.com/meetingcoverage/aad/56593 [Last accessed 2018 Apr 4
- Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949–961.
- Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA. CISION. Chicago, IL: CISION, 2016. Available at: https://www.prnewswire.com/news-releases/can-fite-advances-towards-a-pivotal-phase-iii-clinical-trial-in-psoriasis-with-piclidenoson-cf101-following-reaching-agreement-with-ema-300354526.html+&cd=1&hl=en&ct=clnk&gl=us [Last accessed 2018 Apr 4
- Mrowietz U, Szepietowski JC, Loewe R, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017;176(3):615–623.
- Scott R. A study comparing upadacitinib (ABT-494) to placebo and to adalimumab in participants with psoriatic arthritis who have an inadequate response to at least one non-biologic disease modifying anti-rheumatic drug (SELECT - PsA 1). ClinicalTrials.gov. Mobile, AL: ClinicalTrials.gov/NIH, 2018. Available at: https://clinicaltrials.gov/ct2/show/NCT03104400 [Last accessed 2018 Apr 4].